| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Autologous CD34+-enriched hematopoietic stem and progenitor cells (Genenta Science) | Phase 2 Clinical | Genenta Science Srl | Carcinoma, Renal Cell; Glioblastoma; Multiple Myeloma | Details | |
| CX-801 | CX-801 | Phase 1 Clinical | Cytomx Therapeutics Inc | Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Melanoma | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Nadofaragene firadenovec | SCH-721015 | Approved | Schering - Plough Sa, Fkd Therapies | Adstiladrin | United States | Urinary Bladder Neoplasms | Ferring Pharmaceuticals A/S | 2022-12-16 | Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Mesothelioma | Details |

BettinastraBe 30, 60325 Frankfurt am Main



